Search

Your search keyword '"Maldarelli, F."' showing total 316 results
Start Over Author "Maldarelli, F."
316 results on '"Maldarelli, F."'

1. Colonization and infection due to carbapenemase-producing Enterobacteriaceae in liver and lung transplant recipients and donor-derived transmission: a prospective cohort study conducted in Italy

Author

Farina, C., Vailati, F., Gesu, G., Vismara, C., Arghittu, M., Colombo, R., Torresani, E., Rossi, L., Conaldi, P.G., Gona, F., Cambieri, P., Marone, P., Venditti, C., Fernandez, A. Garcia, Mancini, C., Cusi, M., De Angelis, L. Henrici, Fossati, L., Finarelli, A.C., De Cillia, C., Sangiorgi, G., Pinna, A.D., Stella, F., Viale, P., Colledan, M., Platto, M., Bonizzoli, M., Peris, A., Torelli, R., Vesconi, S., Cibelli, E., De Carlis, L., De Gasperi, A., Ravini, M., Carrinola, R., Coluccio, E., Dondossola, D., Rossi, G., Santambrogio, L., Tosi, D., Feltrin, G., Rago, C., Cillo, U., Da Riva, A., Rea, F., Sparacino, V., Bertani, A., Canzonieri, M., Gridelli, B., Mularoni, A., Spada, M., Carrara, E., D’Armini, A. Maria, Paladini, P., Adorno, D., Valeri, M., Caprio, M., Di Ciaccio, P., Puoti, F., Berloco, P., D’Auria, B., Maldarelli, F., Paglialunga, G., Pugliese, F., Rossi, M., Venuta, F., Amoroso, A., Giacometti, R., Rinaldi, M., Salizzoni, M., Errico, G., Gagliotti, C., Monaco, M., Masiero, L., Gaibani, P., Ambretti, S., Landini, M.P., D’Arezzo, S., Di Caro, A., Parisi, S.G., Palù, G., Vespasiano, F., Morsillo, F., Moro, M.L., Procaccio, F., Ricci, A., Grossi, P.A., Pantosti, A., and Nanni Costa, A.

Published
2019
Full Text
View/download PDF

2. Immunotherapy: UNMET NEED: DEVELOPING TCR-T CELL THERAPIES FOR HIV PATIENTS WITH HPV-ASSOCIATED CANCERS

Author

Franco, Z., primary, Black, M., additional, Jin, J., additional, Zhang, L., additional, Doran, S., additional, Maldarelli, F., additional, Ramaswami, R., additional, Lurain, K., additional, Cai, Y., additional, Prochazkova, M., additional, Fuksenko, T., additional, Hinrichs, C.S., additional, Stroncek, D., additional, Highfill, S.L., additional, Gulley, J.L., additional, and Norberg, S.M., additional

Published
2023
Full Text
View/download PDF

10. Von Willebrand factor with increased binding capacity is associated with reduced platelet aggregation but enhanced agglutination in COVID-19 patients: another COVID-19 paradox?

Author

Ruberto, F., Chistolini, A., Curreli, M., Frati, G., Marullo, A. G. M., Biondi-Zoccai, G., Mancone, M., Sciarretta, S., Miraldi, F., Alessandri, F., Ceccarelli, G., Barone, F., Santoro, C., Alvaro, D., Pugliese, F., Pulcinelli, F. M., Albante, A., Antonelli, G., Araimo-Morselli, F., Auricchio, D., Bilotta, F., Brisciani, G. B. -Z. M., Bruno, K., Cappannoli, A., Cardinale, V., Celli, P., Consolo, S., Croce, C., Crocitti, B., D'Ettorre, G., De Daniela, L., De Lazzaro, F., Fedele, F., Galardo, G., Giannetti, L., Ianni, S., Imperiale, C., Maestrini, V., Magnanimi, E., Maldarelli, F., Martelli, S., Mastroianni, C., Messina, T., Pattelli, E., Pecorari, F., Perrella, S., Piazzolla, M., Portieri, M., Ratini, F., Ricci, C., Santopietro, Pietro, Tellan, G., Titi, L., Tordiglione, P., Tosi, A., and Trigilia, F.

Subjects
Male, Platelet Aggregation, vonWillebrand factor, 030204 cardiovascular system & hematology, Platelet membrane glycoprotein, chemistry.chemical_compound, 0302 clinical medicine, hemic and lymphatic diseases, Platelet, 030212 general & internal medicine, Aged, 80 and over, biology, Hematology, Middle Aged, Host-Pathogen Interactions, Female, Arachidonic acid, Cardiology and Cardiovascular Medicine, Protein Binding, circulatory and respiratory physiology, Adult, Blood Platelets, Platelets, Agglutination, congenital, hereditary, and neonatal diseases and abnormalities, medicine.medical_specialty, Platelet Function Tests, Article, Von Willebrand factor, reduced platelet aggregation, agglutination, COVID‑19, 03 medical and health sciences, Antigen, Von Willebrand factor, Internal medicine, von Willebrand Factor, medicine, Humans, Platelet activation, Ristocetin, Aged, SARS-CoV-2, business.industry, COVID-19, Thrombosis, Covid 19, Agglutination (biology), Endocrinology, chemistry, biology.protein, business
Abstract

Patients with Coronavirus-associated disease-2019 (COVID-19) display alterations of the hemostatic system and the presence of a prothrombotic status frequently leading to vascular complications. However, the impact of COVID-19 on platelet activity, aggregation and agglutination still needs to be clarified. We measured total levels of von Willebrand factor (vWF) and vWF binding to the platelet glycoprotein (Gp) complex (GPIb-IX-V), in a cohort of COVID-19 patients admitted to the intensive care unit of our Institution. Moreover, we evaluated platelet aggregation in response to agonists (ADP, collagen, arachidonic acid) and platelet agglutination in response to ristocetin. We found that levels of vWF antigen and the active form of vWF binding to platelets (vWF:RCo), were markedly increased in these patients. These results were associated with higher agglutination rates induced by ristocetin, thereby indirectly indicating an increased capability of vWF to bind to platelets. Conversely, we found that platelet aggregation in response to both ADP and collagen was lower in COVID-19 patients compared to healthy volunteers. This study shows that COVID-19 is associated with increased vWF-induced platelet agglutination but reduced platelet responsivity to aggregation stimuli. Our findings have translational relevance since platelet adhesion to vWF may represent a marker to predict possible complications and better delineate therapeutic strategies in COVID-19 patients. Electronic Supplementary Material The online version of this article (10.1007/s11239-020-02339-6) contains supplementary material, which is available to authorized users.

Published
2021
Full Text
View/download PDF

13. Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy

Author

Uldrick, TS, Adams, S, Fromentin, R, Roche, M, Fling, SP, Goncalves, PH, Lurain, K, Ramaswami, R, Wang, C-CJ, Gorelick, RJ, Welker, JL, O'Donoghue, L, Choudhary, H, Lifson, JD, Rasmussen, TA, Rhodes, A, Tumpach, C, Yarchoan, R, Maldarelli, F, Cheever, MA, Sekaly, R, Chomont, N, Deeks, SG, Lewin, SR, Uldrick, TS, Adams, S, Fromentin, R, Roche, M, Fling, SP, Goncalves, PH, Lurain, K, Ramaswami, R, Wang, C-CJ, Gorelick, RJ, Welker, JL, O'Donoghue, L, Choudhary, H, Lifson, JD, Rasmussen, TA, Rhodes, A, Tumpach, C, Yarchoan, R, Maldarelli, F, Cheever, MA, Sekaly, R, Chomont, N, Deeks, SG, and Lewin, SR

Abstract

In people living with HIV (PLWH) on antiretroviral therapy (ART), virus persists in a latent form where there is minimal transcription or protein expression. Latently infected cells are a major barrier to curing HIV. Increasing HIV transcription and viral production in latently infected cells could facilitate immune recognition and reduce the pool of infected cells that persist on ART. Given that programmed cell death protein 1 (PD-1) expressing CD4+ T cells are preferentially infected with HIV in PLWH on ART, we aimed to determine whether administration of antibodies targeting PD-1 would reverse HIV latency in vivo. We therefore evaluated the impact of intravenous administration of pembrolizumab every 3 weeks on HIV latency in 32 PLWH and cancer on ART. After the first infusion of anti-PD-1, we observed a median 1.32-fold increase in unspliced HIV RNA and 1.61-fold increase in unspliced RNA:DNA ratio in sorted blood CD4+ T cells compared to baseline. We also observed a 1.65-fold increase in plasma HIV RNA. The frequency of CD4+ T cells with inducible virus evaluated using the tat/rev limiting dilution assay was higher after 6 cycles compared to baseline. Phylogenetic analyses of HIV env sequences in a participant who developed low concentrations of HIV viremia after 6 cycles of pembrolizumab did not demonstrate clonal expansion of HIV-infected cells. These data are consistent with anti-PD-1 being able to reverse HIV latency in vivo and support the rationale for combining anti-PD-1 with other interventions to reduce the HIV reservoir.

Published
2022

16. Integration in oncogenes plays only a minor role in determining the in vivo distribution of HIV integration sites before or during suppressive antiretroviral therapy.

Author

Swanstrom, R, Coffin, JM, Bale, MJ, Wells, D, Guo, S, Luke, B, Zerbato, JM, Sobolewski, MD, Sia, T, Shao, W, Wu, X, Maldarelli, F, Kearney, MF, Mellors, JW, Hughes, SH, Swanstrom, R, Coffin, JM, Bale, MJ, Wells, D, Guo, S, Luke, B, Zerbato, JM, Sobolewski, MD, Sia, T, Shao, W, Wu, X, Maldarelli, F, Kearney, MF, Mellors, JW, and Hughes, SH

Abstract

HIV persists during antiretroviral therapy (ART) as integrated proviruses in cells descended from a small fraction of the CD4+ T cells infected prior to the initiation of ART. To better understand what controls HIV persistence and the distribution of integration sites (IS), we compared about 15,000 and 54,000 IS from individuals pre-ART and on ART, respectively, with approximately 395,000 IS from PBMC infected in vitro. The distribution of IS in vivo is quite similar to the distribution in PBMC, but modified by selection against proviruses in expressed genes, by selection for proviruses integrated into one of 7 specific genes, and by clonal expansion. Clones in which a provirus integrated in an oncogene contributed to cell survival comprised only a small fraction of the clones persisting in on ART. Mechanisms that do not involve the provirus, or its location in the host genome, are more important in determining which clones expand and persist.

Published
2021

18. A randomized trial of vorinostat with treatment interruption after initiating antiretroviral therapy during acute HIV-1 infection

Author

Kroon, EDMD, Ananworanich, J, Pagliuzza, A, Rhodes, A, Phanuphak, N, Trautmann, L, Mitchell, JL, Chintanaphol, M, Intasan, J, Pinyakorn, S, Benjapornpong, K, Chang, JJ, Colby, DJ, Chomchey, N, Fletcher, JLK, Eubanks, K, Yang, H, Kapson, J, Dantanarayana, A, Tennakoon, S, Gorelick, RJ, Maldarelli, F, Robb, ML, Kim, JH, Spudich, S, Chomont, N, Phanuphak, P, Lewin, SR, de Souza, MS, Kroon, EDMD, Ananworanich, J, Pagliuzza, A, Rhodes, A, Phanuphak, N, Trautmann, L, Mitchell, JL, Chintanaphol, M, Intasan, J, Pinyakorn, S, Benjapornpong, K, Chang, JJ, Colby, DJ, Chomchey, N, Fletcher, JLK, Eubanks, K, Yang, H, Kapson, J, Dantanarayana, A, Tennakoon, S, Gorelick, RJ, Maldarelli, F, Robb, ML, Kim, JH, Spudich, S, Chomont, N, Phanuphak, P, Lewin, SR, and de Souza, MS

Abstract

OBJECTIVE AND DESIGN: A randomized, open-label pilot study in individuals treated with antiretroviral therapy (ART) since acute HIV infection (AHI) with a regimen including a histone deacetylase inhibitor to induce HIV from latency and control HIV replication during subsequent treatment interruption (TI). METHODS: Fifteen participants who initiated ART at AHI were randomized to vorinostat/hydroxychloroquine/maraviroc (VHM) plus ART (n ​= ​10) or ART alone (n ​= ​5). The VHM arm received three 14-day vorinostat cycles within 10 weeks before TI. ART was resumed for plasma viral load (VL) ​> ​1,000 HIV RNA copies/mL. Primary outcome was proportion of participants on VHM ​+ ​ART versus ART only with VL ​< ​50 copies/mL for 24 weeks after TI. RESULTS: Fifteen participants on ART (median: 178 weeks: range 79-295) enrolled. Two on VHM ​+ ​ART experienced serious adverse events. Fourteen participants underwent TI; all experienced VL rebound with no difference in time between arms: VHM ​+ ​ART (n ​= ​9) median: 4 weeks and ART only (n ​= ​5) median: 5 weeks. VHM induced a 2.2-fold increase in VL (p ​= ​0.008) by single-copy HIV RNA assay after the first cycle. Neopterin levels increased significantly following the first two cycles. After VHM treatment, the frequencies of peripheral blood mononuclear cells harboring total HIV DNA and cell-associated RNA were unchanged. All participants achieved VL suppression following ART re-initiation. CONCLUSIONS: Administration of VHM increased HIV VL in plasma, but this was not sustained. VHM did not impact time to viral rebound following TI and had no impact on the size of the HIV reservoir, suggesting that HIV reservoir elimination will require alternative treatment strategies.

Published
2020

20. Infections in liver and lung transplant recipients. A national prospective cohort

Author

Gagliotti, Carlo, Morsillo, Filomena, Moro, Maria Luisa, Masiero, Lucia, Procaccio, Francesco, Vespasiano, Francesca, Pantosti, Annalisa, Monaco, Monica, Errico, Giulia, Ricci, Andrea, Grossi, Paolo, Nanni Costa, Alessandro, Adorno, D., Ambretti, S., Amoroso, A., Arghittu, M., Berloco, P., Bertani, A., Bonizzoli, M., Cambieri, P., Canzonieri, M., Caprio, M., Carrara, E., Carrinola, R., Cibelli, E., Cillo, U., Colledan, M., Colombo, R., Coluccio, E., Conaldi, P. G., Cusi, M., D’Armini, A. M., da Riva, A., D’Auria, B., de Carlis, L., de Cillia, C., de Gasperi, A., Di Caro, A., Di Ciaccio, P., Dondossola, D., Farina, C., Feltrin, G., Finarelli, A. C., Fossati, L., Gaibani, P., Garcia Fernandez, A., Gesu, G., Giacometti, R., Gona, F., Gridelli, B., Henrici de Angelis, L., Landini, M. P., Maldarelli, F., Mancini, C., Marone, P., Mularoni, A., Paglialunga, G., Paladini, P., Palù, G., Parisi, S., Peris, A., Pinna, A. D., Platto, M., Pugliese, F., Puoti, F., Rago, C., Ravini, M., Rea, F., Rinaldi, M., Rossi, G., Rossi, L., Rossi, M., Salizzoni, M., Sangiorgi, G., Santambrogio, L., Spada, M., Sparacino, V., Stella, F., Torelli, R., Torresani, E., Tosi, D., Vailati, F., Valeri, M., Venuta, F., Vesconi, S., Viale, P., Vismara, C., Gagliotti, C, Morsillo, F, Moro, M, Masiero, L, Procaccio, F, Vespasiano, F, Pantosti, A, Monaco, M, Errico, G, Ricci, A, Grossi, P, Nanni Costa, A, Adorno, D, Ambretti, S, Amoroso, A, Arghittu, M, Berloco, P, Bertani, A, Bonizzoli, M, Cambieri, P, Canzonieri, M, Caprio, M, Carrara, E, Carrinola, R, Cibelli, E, Cillo, U, Colledan, M, Colombo, R, Coluccio, E, Conaldi, P, Cusi, M, D’Armini, A, da Riva, A, D’Auria, B, de Carlis, L, de Cillia, C, de Gasperi, A, Di Caro, A, Di Ciaccio, P, Dondossola, D, Farina, C, Feltrin, G, Finarelli, A, Fossati, L, Gaibani, P, Garcia Fernandez, A, Gesu, G, Giacometti, R, Gona, F, Gridelli, B, Henrici de Angelis, L, Landini, M, Maldarelli, F, Mancini, C, Marone, P, Mularoni, A, Paglialunga, G, Paladini, P, Palù, G, Parisi, S, Peris, A, Pinna, A, Platto, M, Pugliese, F, Puoti, F, Rago, C, Ravini, M, Rea, F, Rinaldi, M, Rossi, G, Rossi, L, Rossi, M, Salizzoni, M, Sangiorgi, G, Santambrogio, L, Spada, M, Sparacino, V, Stella, F, Torelli, R, Torresani, E, Tosi, D, Vailati, F, Valeri, M, Venuta, F, Vesconi, S, Viale, P, Vismara, C, Gagliotti, Carlo, Morsillo, Filomena, Moro, Maria Luisa, Masiero, Lucia, Procaccio, Francesco, Vespasiano, Francesca, Pantosti, Annalisa, Monaco, Monica, Errico, Giulia, Ricci, Andrea, Grossi, Paolo, Costa, Alessandro Nanni, Adorno, Domenico, Ambretti, Simone, Amoroso, Antonio, Arghittu, Milena, Berloco, Pasquale, Bertani, Alessandro, Bonizzoli, Manuela, Cambieri, Patrizia, Canzonieri, Marco, Caprio, Mario, Carrara, Elena, Carrinola, Rosaria, Cibelli, Eva, Cillo, Umberto, Colledan, Michele, Colombo, Rosaria, Coluccio, Elena, Conaldi, Pier Giulio, Cusi, Mariagrazia, D’Armini, Andrea Maria, Da Riva, Adelaide, D'Auria, Bianca, De Carlis, Luciano, De Cillia, Carlo, De Gasperi, Andrea, Di Caro, Antonino, Di Ciaccio, Paola, Dondossola, Daniele, Farina, Claudio, Feltrin, Giuseppe, Finarelli, Alba Carola, Fossati, Lucina, Gaibani, Paolo, Fernandez, Aurora Garcia, Gesu, Giovanni, Giacometti, Raffaella, Gona, Floriana, Gridelli, Bruno, De Angelis, Lucia Henrici, Landini, Maria Paola, Maldarelli, Federica, Mancini, Carlo, Marone, Piero, Mularoni, Alessandra, Paglialunga, Giulia, Paladini, Piero, Palù, Giorgio, Parisi, Saverio, Peris, Adriano, Pinna, Antonio Daniele, Platto, Marco, Pugliese, Francesco, Puoti, Francesca, Rago, Claudio, Ravini, Mario, Rea, Federico, Rinaldi, Mauro, Rossi, Giorgio, Rossi, Lucia, Rossi, Massimo, Salizzoni, Mauro, Sangiorgi, Gabriela, Santambrogio, Luigi, Spada, Marco, Sparacino, Vito, Stella, Franco, Torelli, Rosanna, Torresani, Erminio, Tosi, Davide, Vailati, Francesca, Valeri, Maurizio, Venuta, Federico, Vesconi, Sergio, Viale, Pierluigi, and Vismara, Chiara

Subjects
Microbiology (medical), Infectious Diseases, Male, 0301 basic medicine, medicine.medical_treatment, Drug Resistance, Transplant Recipient, 030230 surgery, Liver transplantation, Postoperative Complications, 0302 clinical medicine, Drug Resistance, Multiple, Bacterial, Medicine, Cumulative incidence, Prospective Studies, Prospective cohort study, Incidence, Incidence (epidemiology), Mortality rate, Bacterial, Bacterial Infections, General Medicine, Middle Aged, lung transplant, Anti-Bacterial Agents, infectious, Italy, Female, Multiple, Adult, Bacteria, Humans, Transplant Recipients, Liver Transplantation, Lung Transplantation, Human, medicine.medical_specialty, 030106 microbiology, Bacterial Infection, Infectious Diseases, transplantation, 03 medical and health sciences, Internal medicine, Anti-Bacterial Agent, Lung transplantation, business.industry, lung transplant, liver transplant, infectious, Transplantation, Prospective Studie, liver transplant, Etiology, Postoperative Complication, business, transplantation
Abstract

Infections are a major complication of solid organ transplants (SOTs). This study aimed to describe recipients’ characteristics, and the frequency and etiology of infections and transplant outcome in liver and lung SOTs, and to investigate exposures associated to infection and death in liver transplant recipients. The study population included recipients of SOTs performed in Italy during a 1-year period in ten Italian lung transplant units and eight liver transplant units. Data on comorbidities, infections, retransplantation, and death were prospectively collected using a web-based system, with a 6-month follow-up. The cumulative incidence of infection was 31.7% and 47.8% in liver and lung transplants, respectively, with most infections occurring within the first month after transplantation. Gram-negatives, which were primarily multidrug-resistant, were the most frequent cause of infection. Death rates were 0.42 per 1000 recipient-days in liver transplants and 1.41 per 1000 recipient-days in lung transplants. Infection after SOT in adult liver recipients is associated to an increased risk of death (OR = 13.25; p-value < 0.001). Given the frequency of infection caused by multidrug-resistant microorganisms in SOT recipients in Italy and the heavy impact of infections on the transplant outcome, the reinforcement of surveillance and control activities to prevent the transmission of multidrug-resistant microorganisms in SOT recipients represents a priority. The implementation of the study protocol in liver and lung transplant units and the sharing of results have increased the awareness about the threat due to antimicrobial resistance in the country.

Published
2018

21. Clones of infected cells arise early in HIV-infected individuals

Author

Bale, M., Maldarelli, F., Kearney, M.F., Wu, X., Luke, B.T., Mellors, J.W., Simonetti, F.R., Coffin, J.M., Hill, S., Zerbato, J.M., Hughes, S.H., Spindler, J., Guo, S., Eron, J.J., Wells, D.W., and Kuruc, J.D.

Abstract

In HIV-infected individuals on long-term antiretroviral therapy (ART), more than 40% of the infected cells are in clones. Although most HIV proviruses present in individuals on long-term ART are defective, including those in clonally expanded cells, there is increasing evidence that clones carrying replication-competent proviruses are common in patients on long-term ART and form part of the HIV reservoir that makes it impossible to cure HIV infection with current ART alone. Given the importance of clonal expansion in HIV persistence, we determined how soon after HIV acquisition infected clones can grow large enough to be detected (clones larger than ca. 1 × 105 cells). We studied 12 individuals sampled in early HIV infection (Fiebig stage III-V/VI) and 5 who were chronically infected. The recently infected individuals were started on ART at or near the time of diagnosis. We isolated more than 6,500 independent integration sites from peripheral blood mononuclear cells before ART was initiated and after 0.5-18 years of suppressive ART. Some infected clones could be detected approximately 4 weeks after HIV infection and some of these clones persisted for years. The results help to explain how the reservoir is established early and persists for years.

Published
2019
Full Text
View/download PDF

26. No evidence of ongoing HIV replication or compartmentalization in tissues during combination antiretroviral therapy: Implications for HIV eradication

Author

Bozzi, G., primary, Simonetti, F. R., additional, Watters, S. A., additional, Anderson, E. M., additional, Gouzoulis, M., additional, Kearney, M. F., additional, Rote, P., additional, Lange, C., additional, Shao, W., additional, Gorelick, R., additional, Fullmer, B., additional, Kumar, S., additional, Wank, S., additional, Hewitt, S., additional, Kleiner, D. E., additional, Hattori, J., additional, Bale, M. J., additional, Hill, S., additional, Bell, J., additional, Rehm, C., additional, Grossman, Z., additional, Yarchoan, R., additional, Uldrick, T., additional, and Maldarelli, F., additional

Published
2019
Full Text
View/download PDF

27. Colonization and infection due to carbapenemase-producing Enterobacteriaceae in liver and lung transplant recipients and donor-derived transmission: a prospective cohort study conducted in Italy

Author

Errico, G., primary, Gagliotti, C., additional, Monaco, M., additional, Masiero, L., additional, Gaibani, P., additional, Ambretti, S., additional, Landini, M.P., additional, D’Arezzo, S., additional, Di Caro, A., additional, Parisi, S.G., additional, Palù, G., additional, Vespasiano, F., additional, Morsillo, F., additional, Moro, M.L., additional, Procaccio, F., additional, Ricci, A., additional, Grossi, P.A., additional, Pantosti, A., additional, Nanni Costa, A., additional, Farina, C., additional, Vailati, F., additional, Gesu, G., additional, Vismara, C., additional, Arghittu, M., additional, Colombo, R., additional, Torresani, E., additional, Rossi, L., additional, Conaldi, P.G., additional, Gona, F., additional, Cambieri, P., additional, Marone, P., additional, Venditti, C., additional, Fernandez, A. Garcia, additional, Mancini, C., additional, Cusi, M., additional, De Angelis, L. Henrici, additional, Fossati, L., additional, Finarelli, A.C., additional, De Cillia, C., additional, Sangiorgi, G., additional, Pinna, A.D., additional, Stella, F., additional, Viale, P., additional, Colledan, M., additional, Platto, M., additional, Bonizzoli, M., additional, Peris, A., additional, Torelli, R., additional, Vesconi, S., additional, Cibelli, E., additional, De Carlis, L., additional, De Gasperi, A., additional, Ravini, M., additional, Carrinola, R., additional, Coluccio, E., additional, Dondossola, D., additional, Rossi, G., additional, Santambrogio, L., additional, Tosi, D., additional, Feltrin, G., additional, Rago, C., additional, Cillo, U., additional, Da Riva, A., additional, Rea, F., additional, Sparacino, V., additional, Bertani, A., additional, Canzonieri, M., additional, Gridelli, B., additional, Mularoni, A., additional, Spada, M., additional, Carrara, E., additional, D’Armini, A. Maria, additional, Paladini, P., additional, Adorno, D., additional, Valeri, M., additional, Caprio, M., additional, Di Ciaccio, P., additional, Puoti, F., additional, Berloco, P., additional, D’Auria, B., additional, Maldarelli, F., additional, Paglialunga, G., additional, Pugliese, F., additional, Rossi, M., additional, Venuta, F., additional, Amoroso, A., additional, Giacometti, R., additional, Rinaldi, M., additional, and Salizzoni, M., additional

Published
2019
Full Text
View/download PDF

28. Donor liver small droplet macrovesicular steatosis is associated with reduced graft survival after liver transplantation

Author

Ferri, F., Molinaro, A., Poli, E., Parlati, L., Lattanzi, B., Mennini, G., Melandro, F., Nudo, F., Pugliese, F., Maldarelli, F., Corsi, A., Riminucci, M., Merli, M., Rossi, M., Corradini, S. G., and Pugliese, Francesco

Subjects
medicine.medical_specialty, Hepatology, large macrovescicular steatosis, business.industry, medicine.medical_treatment, Small droplet, large macrovescicular steatosis, small macrovescicular steatosis, HCV, liver transplant, Liver transplantation, small macrovescicular steatosis, Macrovesicular steatosis, Gastroenterology, liver transplant, Internal medicine, HCV, Medicine, Graft survival, Living donor liver transplantation, business
Published
2018

29. Donor liver small droplet macrovesicular steatosis is associated with reduced graft survival after liver transplantation

Author

Ferri, F., primary, Molinaro, A., additional, Poli, E., additional, Parlati, L., additional, Lattanzi, B., additional, Mennini, G., additional, Melandro, F., additional, Nudo, F., additional, Pugliese, F., additional, Maldarelli, F., additional, Corsi, A., additional, Riminucci, M., additional, Merli, M., additional, Rossi, M., additional, and Corradini, S.G., additional

Published
2018
Full Text
View/download PDF

30. Infections in liver and lung transplant recipients: a national prospective cohort

Author

Gagliotti, C, Morsillo, F, Moro, M, Masiero, L, Procaccio, F, Vespasiano, F, Pantosti, A, Monaco, M, Errico, G, Ricci, A, Grossi, P, Nanni Costa, A, Adorno, D, Ambretti, S, Amoroso, A, Arghittu, M, Berloco, P, Bertani, A, Bonizzoli, M, Cambieri, P, Canzonieri, M, Caprio, M, Carrara, E, Carrinola, R, Cibelli, E, Cillo, U, Colledan, M, Colombo, R, Coluccio, E, Conaldi, P, Cusi, M, D’Armini, A, da Riva, A, D’Auria, B, de Carlis, L, de Cillia, C, de Gasperi, A, Di Caro, A, Di Ciaccio, P, Dondossola, D, Farina, C, Feltrin, G, Finarelli, A, Fossati, L, Gaibani, P, Garcia Fernandez, A, Gesu, G, Giacometti, R, Gona, F, Gridelli, B, Henrici de Angelis, L, Landini, M, Maldarelli, F, Mancini, C, Marone, P, Mularoni, A, Paglialunga, G, Paladini, P, Palù, G, Parisi, S, Peris, A, Pinna, A, Platto, M, Pugliese, F, Puoti, F, Rago, C, Ravini, M, Rea, F, Rinaldi, M, Rossi, G, Rossi, L, Rossi, M, Salizzoni, M, Sangiorgi, G, Santambrogio, L, Spada, M, Sparacino, V, Stella, F, Torelli, R, Torresani, E, Tosi, D, Vailati, F, Valeri, M, Venuta, F, Vesconi, S, Viale, P, Vismara, C, Gagliotti, C, Morsillo, F, Moro, M, Masiero, L, Procaccio, F, Vespasiano, F, Pantosti, A, Monaco, M, Errico, G, Ricci, A, Grossi, P, Nanni Costa, A, Adorno, D, Ambretti, S, Amoroso, A, Arghittu, M, Berloco, P, Bertani, A, Bonizzoli, M, Cambieri, P, Canzonieri, M, Caprio, M, Carrara, E, Carrinola, R, Cibelli, E, Cillo, U, Colledan, M, Colombo, R, Coluccio, E, Conaldi, P, Cusi, M, D’Armini, A, da Riva, A, D’Auria, B, de Carlis, L, de Cillia, C, de Gasperi, A, Di Caro, A, Di Ciaccio, P, Dondossola, D, Farina, C, Feltrin, G, Finarelli, A, Fossati, L, Gaibani, P, Garcia Fernandez, A, Gesu, G, Giacometti, R, Gona, F, Gridelli, B, Henrici de Angelis, L, Landini, M, Maldarelli, F, Mancini, C, Marone, P, Mularoni, A, Paglialunga, G, Paladini, P, Palù, G, Parisi, S, Peris, A, Pinna, A, Platto, M, Pugliese, F, Puoti, F, Rago, C, Ravini, M, Rea, F, Rinaldi, M, Rossi, G, Rossi, L, Rossi, M, Salizzoni, M, Sangiorgi, G, Santambrogio, L, Spada, M, Sparacino, V, Stella, F, Torelli, R, Torresani, E, Tosi, D, Vailati, F, Valeri, M, Venuta, F, Vesconi, S, Viale, P, and Vismara, C

Abstract

Infections are a major complication of solid organ transplants (SOTs). This study aimed to describe recipients’ characteristics, and the frequency and etiology of infections and transplant outcome in liver and lung SOTs, and to investigate exposures associated to infection and death in liver transplant recipients. The study population included recipients of SOTs performed in Italy during a 1-year period in ten Italian lung transplant units and eight liver transplant units. Data on comorbidities, infections, retransplantation, and death were prospectively collected using a web-based system, with a 6-month follow-up. The cumulative incidence of infection was 31.7% and 47.8% in liver and lung transplants, respectively, with most infections occurring within the first month after transplantation. Gram-negatives, which were primarily multidrug-resistant, were the most frequent cause of infection. Death rates were 0.42 per 1000 recipient-days in liver transplants and 1.41 per 1000 recipient-days in lung transplants. Infection after SOT in adult liver recipients is associated to an increased risk of death (OR = 13.25; p-value < 0.001). Given the frequency of infection caused by multidrug-resistant microorganisms in SOT recipients in Italy and the heavy impact of infections on the transplant outcome, the reinforcement of surveillance and control activities to prevent the transmission of multidrug-resistant microorganisms in SOT recipients represents a priority. The implementation of the study protocol in liver and lung transplant units and the sharing of results have increased the awareness about the threat due to antimicrobial resistance in the country

Published
2018

32. Interim safety analysis of cancer immunotherapy trials Network – 12 (CITN-12): a Phase 1 study of pembrolizumab in patients with HIV and cancer

Author

Uldrick, T.S., primary, ‘Mac’ Cheever, M.A., additional, Gonçalves, P.H., additional, Fling, S., additional, Aleman, K., additional, Emu, B., additional, Ernstoff, M.S., additional, Gorelick, R., additional, Kaiser, J., additional, E Kohrt, H., additional, Lacroix, A., additional, Lindsley, M., additional, M Lundgren, L., additional, Lurain, K., additional, Maldarelli, F., additional, Parsons, C., additional, Sharon, E., additional, Widell, A., additional, and Yarchoan, R., additional

Published
2017
Full Text
View/download PDF

38. Retrovirus Integration Database (RID): A public database for retroviral insertion sites into host genomes

Author

Shao, W, Shan, J, Kearney, MF, Wu, X, Maldarelli, F, Mellors, JW, Luke, B, Coffin, JM, Hughes, SH, Shao, W, Shan, J, Kearney, MF, Wu, X, Maldarelli, F, Mellors, JW, Luke, B, Coffin, JM, and Hughes, SH

Abstract

The NCI Retrovirus Integration Database is a MySql-based relational database created for storing and retrieving comprehensive information about retroviral integration sites, primarily, but not exclusively, HIV-1. The database is accessible to the public for submission or extraction of data originating from experiments aimed at collecting information related to retroviral integration sites including: the site of integration into the host genome, the virus family and subtype, the origin of the sample, gene exons/introns associated with integration, and proviral orientation. Information about the references from which the data were collected is also stored in the database. Tools are built into the website that can be used to map the integration sites to UCSC genome browser, to plot the integration site patterns on a chromosome, and to display provirus LTRs in their inserted genome sequence. The website is robust, user friendly, and allows users to query the database and analyze the data dynamically. Availability: https://rid.ncifcrf.gov; or http://home.ncifcrf.gov/hivdrp/resources.htm.

Published
2016

44. Uncovering mechanisms of HIV persistence in HIV controllers by HIV sequence analysis in CD4 T cell subsets

Author

Boritz, E., primary, Darko, S., additional, Simonetti, F., additional, Wells, D., additional, Wu, X., additional, Swaszek, L., additional, Wolf, G., additional, Hoh, R., additional, Vostal, A., additional, Ober, A., additional, Hughes, M., additional, Bunis, D., additional, Migueles, S., additional, Casazza, J., additional, Koup, R., additional, Connors, M., additional, Moir, S., additional, Martin, J., additional, Maldarelli, F., additional, Hughes, S., additional, Deeks, S., additional, and Douek, D., additional

Published
2015
Full Text
View/download PDF

50. A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection

Author

Dybul, M, Nies-Kraske, E, Dewar, R, Maldarelli, F, Hallahan, CW, Daucher, M, Piscitelli, SC, Ehler, L, Weigand, A, Palmer, S, Metcalf, JA, Davey, RT, Kress, DMR, Powers, A, Beck, Ingrid, Frenkel, L, Baseler, M, Coffin, J, Fauci, AS, and University of Groningen

Subjects
LIPODYSTROPHY, PROTEASE INHIBITORS, REVERSE-TRANSCRIPTASE, BODY-COMPOSITION, NEVIRAPINE, HUMAN-IMMUNODEFICIENCY-VIRUS, RISK-FACTORS, virus diseases, STRUCTURED TREATMENT INTERRUPTIONS, TYPE-1 RNA, HIV/AIDS TREATMENT
Abstract

Background. We previously demonstrated that short-cycle structured intermittent therapy ( SIT; 7 days without therapy followed by 7 days with antiretroviral therapy [ART]) with a ritonavir-boosted, indinavir-based, twice-daily regimen maintained suppression of plasma HIV viremia while reducing serum levels of lipids. Adherence to such a regimen may be problematic for certain patients. Methods. Eight patients with a history of receiving combination ART that maintained suppression of plasma HIV RNA to Results. For 7 patients, suppression of plasma HIV RNA to Conclusion. A once-daily short-cycle SIT regimen maintained suppression of plasma HIV RNA while preserving CD4(+) T cell counts. Such a regimen may have importance in resource-limited settings where the monetary cost of continuous ART is prohibitive.

Published
2004

Catalog

Books, media, physical & digital resources
See catalog results